ClinicalTrials.gg
RecruitingNCT07488949Updated Mar 23, 2026

Doxycycline and Progestin Therapy for Chronic Endometritis(CE) in Patients With Recurrent Reproductive Failure(RRF)

An interventional study of Doxycycline combined with Medroxyprogesterone and Doxycycline combined with placebo in Chronic Endometritis, sponsored by Fang Wang. Recruiting at 1 site in China. Open to female participants aged 20 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-03-23.

Sponsored by Fang Wang · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year 11 months after the study started (first participant enrolled Apr 2024, registered Mar 2026).
  • Started Apr 2024; still recruiting 2 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,000
Allocation
Randomized
Ages
20 Years to 45 Years
Sex
Female
01

Study summary

A Prospective Randomized Controlled Trial, the goal of this clinical trial is to evaluate the efficacy and safety of doxycycline alone versus doxycycline plus medroxyprogesterone acetate (MPA) in women with chronic endometritis (CE), and to assess subsequent reproductive outcomes. Participants will be randomly assigned to one of two groups and will receive the assigned treatment. Participants will be followed for reproductive outcomes, including pregnancy , ongoing pregnancy, spontaneous miscarriage, and live birth.

02

Conditions studied

  • Chronic Endometritis

Browse trials for

03

In context

Endometritis

50 studies on the registry are indexed under Endometritis; 11 are open to participants now.

This study's planned enrollment of 1,000 is above the median of 300 across 38 interventional studies indexed under Endometritis.

Browse Endometritis studies →

Lead sponsor

Fang Wang is the lead sponsor of 4 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • women aged 20-45 years;
  • plans to conceive within 12 months;
  • chronic endometritis(CE) confirmed by endometrial CD138 immunohistochemistry (IHC);
  • a diagnosis of recurrent reproductive failure(RRF);
  • willingness to undergo hysteroscopy and endometrial ;
  • no to the study medications.

Exclusion criteria

Exclusion Criteria:

  • acute genital tract infection, gynecologic , endometrial hyperplasia, or uterine fibroids;
  • pregnancy or lactation;
  • to hysteroscopy or anesthesia;
  • use of antibiotics, , estrogens, or progestins within 3 months before trial initiation;
  • allergy to doxycycline or medroxyprogesterone acetate(MPA);
  • abnormal semen parameters in the male partner.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
1,000 participants (estimated)

Study arms

  • Experimental
    doxycycline combined with medroxyprogesterone acetate(MPA)

    Drug: Doxycycline combined with Medroxyprogesterone

  • Active comparator
    doxycycline combined with placebo

    Drug: Doxycycline combined with placebo

Interventions

  • DrugDoxycycline combined with Medroxyprogesterone

    Drug pages: DoxycyclineStudies of DoxycyclineDoxycycline pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · MedroxyprogesteroneStudies of MedroxyprogesteroneMedroxyprogesterone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    doxycycline 200 mg/day (100 mg twice daily) combined with medroxyprogesterone acetate(MPA) 24 mg/day (8 mg three times daily) for 14 days

  • DrugDoxycycline combined with placebo

    doxycycline 200 mg/day (100 mg twice daily) with placebo 24 mg/day (8 mg three times daily) for 14 days

06

What researchers measure

Primary outcomes

  1. Cure rate of chronic endometritis

    Time frame: At 8 weeks after completion of treatment

Secondary outcomes

  1. pregnancy rate

    Pregnancy was defined as a pregnancy confirmed after completion of treatment, including biochemical pregnancy. Only the first pregnancy after completion of treatment was included in the analysis.

    Time frame: From completion of treatment to the end of the follow-up period, with a minimum follow-up of 6 months.

  2. Live birth rate

    Live birth was defined as delivery of a live infant at or beyond 24 weeks of gestation. Only the first pregnancy after completion of treatment was included in the analysis.

    Time frame: From completion of treatment to the end of follow-up, with a minimum follow-up of 6 months

  3. Rate of pregnancy loss

    Pregnancy loss was defined as spontaneous loss of a pregnancy before 24 weeks of gestation. Only the first pregnancy after completion of treatment was included in the analysis.

    Time frame: From completion of treatment to the end of follow-up, with a minimum follow-up of 6 months

  4. sustained pregnancy rate

    Sustained pregnancy was defined as a pregnancy lasting for at least 12 weeks of gestation. Only the first pregnancy after completion of treatment was included in the analysis.

    Time frame: From completion of treatment to the end of follow-up, with a minimum follow-up of 6 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2024 (actual). Primary completion is estimated for Dec 2030, 80 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2026
First posted
Mar 23, 2026
StartActual
Apr 9, 2024
Primary completionEst.
Dec 31, 2030
CompletionEst.
Dec 31, 2031
Last update
Mar 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07488949
Lead sponsor
Fang Wang
Responsible party
Fang Wang (Chief physician, Lanzhou University Second Hospital) — Sponsor-investigator
First posted
Mar 23, 2026
Start date
Apr 9, 2024
Primary completion
Dec 31, 2030 (estimated)
Completion
Dec 31, 2031 (estimated)
Last update
Mar 23, 2026

Study contacts

Fang Wang
Contact
ery_fwang@lzu.edu.cn
13919302888
Fang Wang
principal investigator · Lanzhou University Second Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Doxycycline · Medroxyprogesterone

Start the discussion